Connect public, paid and private patent data with Google Patents Public Datasets

Process for micronizing slightly-soluble drug

Download PDF

Info

Publication number
US5202129A
US5202129A US07563091 US56309190A US5202129A US 5202129 A US5202129 A US 5202129A US 07563091 US07563091 US 07563091 US 56309190 A US56309190 A US 56309190A US 5202129 A US5202129 A US 5202129A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
drug
sugar
process
diameter
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US07563091
Inventor
Masayoshi Samejima
Kazuo Noda
Masao Kobayashi
Takashi Osawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Seiyaku Co Ltd
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Abstract

A process for micronizing a slightly-soluble drug characterized by subjecting a mixture of said drug and a sugar or sugar alcohol to high-speed stirring comminution or impact comminution in order to produce a micronized drug having an average diameter of less than about 2-3 mm. Also provided is a pharmaceutical formulation which comprises the micronized drug.

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a process for micronizing a slightly-soluble drug. More specifically, it relates to a process for micronizing a slightly-soluble drug, which comprises grinding said drug in the presence of a sugar or sugar alcohol of a lower molecular weight as a grinding aid, and to a pharmaceutical formulation containing the resultant ultrafine drug as an active ingredient.

2. Description of the Related Arts

When a pharmaceutical formulation containing a drug is orally administered to subjects, a dissolution step is essential for the drug to be absorbed through gastrointestinal tract. It has long been recognized that a slightly-soluble drug often shows insufficient bioavailability because of the poor solubility in gastrointestinal fluids, which compels said drug to pass through the site of absorption before it completely dissolves in the fluids. Various attempts have been made from the aspect of pharmaceutics to improve and increase the absorption efficiency of a slightly-soluble drug in gastrointestinal tract.

Specific examples of said attempts employed for preparing improved formulations include following countermeasures.

1) Providing a soft gelatin capsule containing a solution of said drug in a nonaqueous solvent.

2) Providing a water-soluble salt of said drug.

3) Providing a solid solution which is prepared by dissolving the drug with a suitable polymer in an organic solvent and drying the solution promptly (see, reference 1 listed at the end of this specification).

4) A drug is dissolved in an organic solvent and adsorbed on a porous material in the form of ultrafine particles so that the surface area may be increased.

5) A drug is pulverized in the presence of an appropriate adduct to obtain an amorphous powder (see, references 3, 4 and 5).

6) A drug is just ground into a fine powder (see, reference 2).

The above countermeasures 1) to 5) are associated with alteration of properties of a drug in molecular level. These countermeasures, although advantageous in some aspects, have several disadvantages described below.

In the method of the above item 1), it is not always easy to find out a suitable nonaqueous solvent. In addition, the capsule size may become too big for oral administration. Furthermore, the production cost may be high.

The second method of the above item 2, where the drug is converted into a water-soluble salt, is not applicable to all kinds of drugs because many drugs may not form such salts. Additionally, formation of a water-soluble salt may be often accompanied by alteration of pharmaceutical activity of the drug and/or decrease its stability. Therefore, this method is just applicable to limited drugs.

The methods of the above items 3 and 4 are not applicable to every drug and the methods require the use of organic solvents which may be harmful to living bodies. Production cost may also be high in these methods.

In the method of the above item 5, a slightly-soluble drug is mixed with an adduct such as (1) β -1,4-glucan, (2) adsorbent, or (3) polyvinylpyrrolidone. The drug is pulverized in the presence of such adduct to obtain the drug in the form of amorphous powder which may exhibit improved dissolution rate and bioavailability. However, the amorphous form is not physically stable and often converted reversibly to more stable crystal form. Consequently, the dispersion or dissolution properties of the drug may be changed as time passes.

The method of the above item 6) differs from those of items 1) to 5) which all change the properties of a drug in molecular level, in that the former contemplates to improve bioavailability of a drug through micronization. The micronization has the following advantages.

a) The alteration of crystal form of a drug is slight or moderate;

b) The operation is safe because no organic solvent is employed;

c) The production cost is low; and

d) The operation is easy.

In general, a milling process (it is also referred to as grinding, pulverization, and the like) is essential in the process of the production of pharmaceutical formulations. Examples of mills commonly used involve dry-type mills, such as jet, ball, vibration, and hammer mill. These dry-type mills are used to grind a drug alone to afford particles of several μm in diameter. However, it is difficult to obtain finer particles by conventional means. Especially, preparation of submicron particles of less than 1 μm in diameter is almost impossible.

This difficulty is associated with peculiar nature inherent to micronized particles that such particles have a tendency to aggregate, adhere, or solidify as the particle size decreases. Thus, it is extremely difficult to grind a drug into ultrafine particles having a diameter of less than several μm by conventional milling procedures. Accordingly, a practically applicable process for preparing ultrafine particles of a drug has long been needed.

SUMMARY OF THE INVENTION

The present inventors have found that ultrafine particles of a slightly-soluble drug, whose average diameter is less than about 2 to 3 μm, preferably less than 1 μm, can be easily obtained by grinding the drug in the presence of a grinding aid selected from a sugar and a sugar alcohol by means of a high-speed stirring mill or impact mill.

Accordingly, in one aspect, this invention provides a process for micronizing slightly-soluble drug characterized by subjecting a mixture of said drug and a sugar or sugar alcohol to high-speed stirring comminution or impact comminution.

This invention also provides a pharmaceutical formulation which comprises, as an active ingredient, a micronized drug produced according to the above process together with suitable excipients or diluents therefor.

DETAILED DESCRIPTION OF THE INVENTION

The term "slightly-soluble drug" herein used refers to a pharmaceutical compound which dissolves in water, particularly at 20° C., at the ratio of 5 mg/ml or less and which is insufficiently absorbed at gastrointestinal tract when it is administered in the form of conventional solid formulations. Specific examples of the slightly-soluble drugs are coronary vasodilators such as nifedipine, nicardipine, nimodipine, dipyridamole, disopyramide, prenylamine lactate, and efloxate; antihypertensives such as dihydroergotoxine and prazosin; steroidal anti-inflammatory agents such as cortisone, dexamethasone, betamethasone, and fluocinolone acetonide; non-steroidal anti-inflammatory agents such as indomethacin, naproxen, and ketoprofen; psychoneurotic agents such as phenytoin, phenacemide, ethylphenacemide, ethotoin, primidone, phensuximide, diazepam, nitrazepam, and clonazepam; cardiacs such as digoxin, digitoxin, and ubidecarenon; diuretics such as spironolactone, triamterene, chlorthalidone, polythiazide, and benzthiazide; chemotherapeutics such as griseofulvin, nalidixic acid, and chloramphenicol; skeletal muscle relaxants such as chlorzoxazone, phenprobamate, and carisoprodol; anticonvulsants such as etomidoline; antihistaminic agents such as diphenhydramine, promethazine, mequitazine, bisbenthiamine, and clemastine fumarate.

Sugars and sugar alcohols used as a grinding aid are selected from pharmaceutically acceptable sugars and sugar alcohols having no influence on the medical effects of an active ingredient. For the purpose of the invention, it is preferable to use sugars or sugar alcohols having a molecular weight of less than 500, and capable of easily dispersing and dissolving in water, whereby improving dissolution rate of the active ingredient. Examples of sugars and sugar alcohols usable in the present invention include xilitol, mannitol, solbitol, arabinose, ribose, xylose, glucose, mannose, galactose, sucrose, lactose, and the like. They can be used alone, or as a mixture of two or more of these compounds. The most preferable sugar is mannitol.

In the process of the invention, one part by weight of an active ingredient is combined with about 2.5 to about 50 parts, preferably about 2.5 to about 20 parts, more preferably about 5 to about 10 parts by weight, of a sugar.

Mills employable in the present process are, for example, dry mills capable of grinding a material into ultrafine particles through a mechanical impact and/or attrition, which are called high-speed stirring mills and impact mills. Specific examples of the preferred mills are cylinder-type mills such as rotating ball mill, vibrating ball mill, tube mill, rod mill, and the like.

The time required for the completion of the present process depends on the properties of the drug and sugar or sugar alcohol, function of the mill, content of the sugar or sugar alcohol in the mixture, and total amount of the mixture to be treated. The grinding time may also be changed according to the strength of impact, and it is generally between 5 to 30 minutes under a strong impact, while it is between 8 to 100 hours under a weak impact. The drug and sugar or sugar alcohol can be used in the present procedure without pre-treatment, but they can be coarsely ground before use.

The mixture which have undergone micronizing treatment according to the process of the present invention contains ultrafine particles of the drug having an average diameter of less than 1 μm. Co-existence of the sugar or sugar alcohol in the mixture after the treatment is advantageous because it has high solubility in water and can disperse into water, whereby increasing dissolution rate of the drug.

The mixture treated according to the process of the invention can be used as such for the preparation of pharmaceutical compositions. Alternatively, after dispersing the mixture into water, the resulting suspension can be subjected to ultrafiltration to remove the sugar or sugar alcohol and subsequently dried to yield a micronized slightly-soluble drug in high purity.

The micronized drug obtained by the invention can be formulated in the form of powders, tablets, granules, capsules, aerosols, suspensions, syrups, ointments, suppositories, and the like, with one or more pharmaceutically acceptable excipients and/or diluents.

The following examples further illustrate the present invention. The examples are not intended to be limiting the scope of the invention in any respect and should not be so construed.

EXAMPLE 1 Micronization of Naproxene in the Presence of D-Mannitol

Naproxene (1 g), a slightly-soluble pharmaceutical compound, was mixed with D-mannitol (9 g, Katayama Chemicals, Ltd.). The mixture was then ground for one hour in a sealed stainless steel vibrational ball mill (Specks, Co., volume: 50 ml) with the aid of two stainless steel balls of 9 mm in diameter.

The size distribution of naproxene in the resultant micronized product was determined in the following manner:

The product obtained above (sample 1), a mixture of separately ground naproxene and D-mannitol (control 1), and naproxene powder (untreated raw material) (control 2) were employed in the experiment. The measurement was conducted using a centrifugal particle size analyzer (SA-CP2, Shimazu Seisakusyo, Japan). The 50% average diameter of naproxene was determined on the basis of volume. The results are shown below:

______________________________________        50% average diameterSample       of naproxene______________________________________Sample 1     0.32 μmControl 1    4.4 μmControl 2     19 μm______________________________________

The influence of the duration of treating time on the particle size was investigated, and it was found that the size was reduced rapidly in the initial stage and almost reached to equilibrium within 30 minutes.

EXAMPLE 2 Micronization of Various Slightly-Soluble Drugs in the Presence of D-mannitol

Slightly-soluble pharmaceutical compounds (each 1 g) were subjected to the micro-grinding procedure as described in Example 1 in the presence of D-mannitol (9 g, Katayama Chemicals, Ltd.) (60 minutes, mixing ratio of 1:9).

The size distribution of the each compound was determined and the 50% average diameter thereof was obtained in the same manner as above. For comparison, each pharmaceutical compound was ground alone. Experimental results are shown in Table 1 below.

              TABLE 1______________________________________Particle Sizes of Various CompoundsMicronized in the Presence of D-mannitol       50% Average Diameter (μm)         Before     After Millingcompound      Milling    alone   mixture______________________________________indomethacin   9         1.3     0.35phenytoin     32         2.7     0.27naproxene     19         4.4     0.32bisbentiamine 12         2.6     0.42chloramphenichol         67         22.0    0.53griseofulvin   6         14.0    0.26oxophosphoric acid          7         3.4     0.1______________________________________

Table 1 shows that the particle size of each micronized compound is less than 1 μm and that the micronizing process of the invention gives ultrafine particles compared with those obtained by grinding without D-mannitol.

EXAMPLE 3 Micronization of Oxophosphoric Acid in the Presence of Various Sugars or Sugar Alcohols

Oxophosphric acid (1 g), a slightly-soluble pharmaceutical compound, was subjected to the micronizing process as described in Example 1 in the presence of each of various sugars (each 9 g) (60 minutes, mixing ratio of 1:9).

The size distribution of oxophosphoric acid was determined and the 50% average diameter thereof was obtained in the same manner as above. As a control, oxophosphoric acid was ground alone. Test results are shown in Table 2 below.

              TABLE 2______________________________________Particle Sizes of Micronized Oxophosphoric AcidSugars      50% average diameter (μm)______________________________________None        3.4glucose     0.22lactose     0.22sucrose     0.22maltose     0.19xilitol     0.21sorbitol    0.22D-mannitol  0.15______________________________________

Table 2 shows that all of the listed sugars are effective to give a micronized oxophsphoric acid having a particle size of less than 1 μm. It can be seen that D-mannitol is the most efficient sugar among others.

EXAMPLE 4 Isolation of Micronized Oxophosphoric Acid

To the micronized product comprising oxophosphoric acid and D-mannitol (10 g, prepared in Example 3) was added a distilled water (100 ml), and the mixture was stirred in order to disperse the acid and also to dissolve mannitol. The resultant suspension was charged in Ultrafiltration System ( Model UHP-62 Toyo Paper, Japan, equipped with a ultrafilter UK-50, 50,000-molecular weight cutoff), and ultrafiltered under pressure to remove dissolved D-mannitol. After the addition of distilled water (100 ml), the ultrafiltration was repeated under pressure with stirring. The solid residue left on the ultrafilter membrane was recovered and dried over phosphorus pentaoxide under reduced pressure for 24 hours at 50° C. to obtain oxophosphoric acid as a ultrafine powder with high purity (purity≧98%). Scanning electron microscope observation revealed that it consisted of particles in the form of fine prismatic crystals having an average diameter of from about 0.1 to 0.4 μm.

The above test shows that the micronized oxophosphoric acid can be purified by subjecting the product to dispersing, ultrafiltering, and drying treatments.

EXAMPLE 5 Micronization of Phenytoin

A mixture of phenytoin (10 g) and D-mannitol (90 g) was ground in a ceramic ball mill (volume: lL; 90 ceramic balls of 20 mm in diameter) at 120 rpm for 48 hours. Size distribution measurement was carried out in the same manner as Example 1 and the 50% average diameter was determined. The 50% average diameter of phenytoin before grinding was 3.2 μm, while it was 0.6 μm after grinding.

The influence of the duration of treating time on the particle size was investigated, and it was found that the size was reduced rapidly in the initial stage and almost reached to equilibrium within 48 hours. Further grinding up to 200 hours gave no change in the particle size.

The following formulation examples are illustrative only and are not intend to limit the scope of the invention.

FORMULATION 1 Suspension Syrups

To a micronized product consisting of chloramphenicol (10 g) and sucrose (90 g) prepared according to the procedure described in Example 4 were added methyl celulose and water, and the mixture was homogenized in a homomixer to obtain a suspension syrup of chloramphenycol.

The average diameters of chloramphenycol particles before and after the micronization, and just after formulation to the suspension syrup, were determined according to the procedure described in Example 1. Average diameter of the particles was 10 μm before micronization, and 0.6 μm after micronization. In suspension syrup, the average diameter of the particles was 0.7 μm when measured immediately after the preparation, and the size remained unchanged after keeping the syrup at room temperature. The test results show that formulation procedure gives no adverse effect to the micronized product, and a stable suspension syrup of chloramphenycol can be obtained while keeping the particle size constant.

FORMULATION 2 Tablets

To a micronized product consisting of griseofulvin and D-mannitol (prepared in Example 2) were added corn starch as a disintegrator and polyvinylpyrrolidone as a binder. The mixture was subjected to a wet granulation. Granules so produced were mixed with magnesium stearate, and the mixture was compressed by means of a tablet machine to yield tablets. The tablets were completely disintegrated in water within 10 minutes when subjected to disintegration test described in the 11th revised edition of Japanese pharmacopoeia. After the disintegration test, size distribution of griseofulvin in the solution was measured by scanning electron micrographic method. The average diameter of griseofulbin in the solution was 0.4 μm.

FORMULATION 3 Granules

Micronized product consisting of oxophosphoric acid and D-mannitol (prepared in Example 2) was admixed with hydroxypropyl cellulose as a binder. The mixture was granulated using a rotary granulator and dried to yield granules. The granules were completely disintegrated in water within 10 minutes when subjected to disintegration test described in the 11th revised edition of Japanese pharmacopoeia. After the disintegration test, size distribution of oxophosphoric acid in the solution was measured in the manner as in Example 1. The average diameter of oxophosphoric acid in the solution was 0.3 μm.

REFERENCES

1. H. Sekikawa, et al., Chem.Pharm.Bull., vol.26, 3033 (1978)

2. R. M. Atkinson, et al., Nature, vol.193, 588 (1962)

3. Y. Nakai, Japanese Patent Publication (kokai) No. 51-32718, and K. Takeo, et al., Japanese Patent Publication (kokai) No. 53-9315

4. M. Matsui, et al., Japanese Patent Publication (kokai) No. 60-8220

5. N. Kaneniwa, et al., Chem.Pharm.Bull., vol.23, 2986 (1975)

6. K. Kigasawa, et al., Yakugaku-Zasshi, vol. 101(8), 723-732 (1981)

Claims (7)

What is claimed is:
1. A process for micronizing a slightly-soluble drug comprising subjecting a mixture of said drug and a sugar or sugar alcohol, the weight ratio of said sugar or sugar alcohol being at least 2.5 or more parts by weight to one part by weight of the drug, to high-speed stirring comminution or impact comminution to give a micronized drug having an average diameter of less than 1 μm.
2. The process of claim 1, wherein the molecular weight of the sugar or sugar alcohol is less than 500.
3. The process of claim 1 or 2, wherein the sugar or sugar alcohol is selected from the group consisting of xylitol, mannitol, sorbitol, arabinose, ribose, xylose, glucose, mannose, galactose, sucrose and lactose.
4. A pharmaceutical formulation which comprises, as an active ingredient, a micronized drug produced according to claim 1 together with suitable excipients or diluents therefor.
5. The process according to claim 1, wherein said weight ratio of sugar or sugar alcohol is about 2.5 to about 50 parts by weight to one part by weight of the drug.
6. The process according to claim 5, wherein said weight ratio of sugar or sugar alcohol is about 2.5 to about 20 parts by weight to one part by weight of the drug.
7. The process according to claim 6, wherein said weight ratio of sugar or sugar alcohol is about 5 to about 10 parts by weight to one part by weight of the drug.
US07563091 1989-08-04 1990-08-03 Process for micronizing slightly-soluble drug Expired - Fee Related US5202129A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP20413289A JP2642486B2 (en) 1989-08-04 1989-08-04 Ultra-fine particles Act of poorly soluble drugs
JP1-204132 1989-08-04

Publications (1)

Publication Number Publication Date
US5202129A true US5202129A (en) 1993-04-13

Family

ID=16485367

Family Applications (1)

Application Number Title Priority Date Filing Date
US07563091 Expired - Fee Related US5202129A (en) 1989-08-04 1990-08-03 Process for micronizing slightly-soluble drug

Country Status (8)

Country Link
US (1) US5202129A (en)
JP (1) JP2642486B2 (en)
KR (1) KR0126465B1 (en)
CA (1) CA2022465C (en)
DE (2) DE69004372D1 (en)
DK (1) DK0411629T3 (en)
EP (1) EP0411629B1 (en)
ES (1) ES2062221T3 (en)

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302400A (en) * 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5460829A (en) * 1991-12-03 1995-10-24 Rhone-Poulenc Rorer S.A. Pharmaceutical compositions based on ebastine or analogues thereof
US5503723A (en) * 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
US5658878A (en) * 1993-06-24 1997-08-19 Ab Astra Therapeutic preparation for inhalation
US5730997A (en) * 1994-08-01 1998-03-24 Kv Pharmaceutical Company Tastemasked liquid pharmaceutical delivery system
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US5952008A (en) * 1993-06-24 1999-09-14 Ab Astra Processes for preparing compositions for inhalation
US6004574A (en) * 1994-12-22 1999-12-21 Astra Aktiebolag Powder formulations containing melezitose as a diluent
US6165976A (en) * 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US6197347B1 (en) 1998-06-29 2001-03-06 Andrx Pharmaceuticals, Inc. Oral dosage for the controlled release of analgesic
WO2002013823A1 (en) * 2000-08-14 2002-02-21 Teva Pharmaceutical Industries Ltd. Micronized torsemide
US6432448B1 (en) * 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6436902B1 (en) 1994-12-22 2002-08-20 Astrazeneca Ab Therapeutic preparations for inhalation
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US6544552B2 (en) 2001-01-11 2003-04-08 Particle And Coating Technologies, Inc. Method of producing porous tablets with improved dissolution properties
US20030129238A1 (en) * 1999-10-29 2003-07-10 Michael Augello Edible MCC/PGA coating composition
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US20030211972A1 (en) * 1993-06-24 2003-11-13 Astrazeneca Ab, A Sweden Corporation Systemic administration of a therapeutic preparation
US6699315B2 (en) 2000-11-28 2004-03-02 Fmc Corporation Edible PGA coating composition
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20040146537A1 (en) * 2003-01-28 2004-07-29 Ramachandran Radhakrishnan Oily wax matrix suspension formulation comprising pharmacologically active agents
US20040171550A1 (en) * 1993-06-24 2004-09-02 Astrazeneca Ab, A Swedish Corporation Compositions for inhalation
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
US20050095272A1 (en) * 2000-11-28 2005-05-05 Fmc Corporation Edible PGA coating composition
US20050152983A1 (en) * 2004-01-08 2005-07-14 Wyeth Directly compressible pharmaceutical composition for the oral administration of CCI-779
US6932962B1 (en) 1994-12-22 2005-08-23 Astrazeneca Ab Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides
US20060002974A1 (en) * 2002-06-21 2006-01-05 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US6994867B1 (en) 2002-06-21 2006-02-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing L-arginine
US7011842B1 (en) 2002-06-21 2006-03-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US20060058272A1 (en) * 1999-08-31 2006-03-16 Juergen Hilman Pharmaceutical composition for use as a contraceptive
US20060062821A1 (en) * 2002-06-21 2006-03-23 Simhambhatla Murthy V Polycationic peptide coatings and methods of making the same
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US7070798B1 (en) 2002-06-21 2006-07-04 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine
US20060160903A1 (en) * 2003-02-24 2006-07-20 Sidney Liang Process for preparing benzhydrylthioacetamide
US7094256B1 (en) 2002-12-16 2006-08-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical device containing polycationic peptides
US20060255323A1 (en) * 2003-11-28 2006-11-16 Mitsubishi Chemichal Corporation Process for producing fine particles of organic compound
US7144585B1 (en) 1999-03-25 2006-12-05 Otsuka Pharmaceutical Co., Ltd. Cilostazol preparation
US20070092576A1 (en) * 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US20070117862A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
WO2007064311A1 (en) * 2001-07-10 2007-06-07 Teva Pharmaceutical Industries Ltd. Micronized mirtazapine
US20070148211A1 (en) * 2005-12-15 2007-06-28 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US20070178166A1 (en) * 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US20080160095A1 (en) * 1993-02-22 2008-07-03 Abraxis Bioscience, Llc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
US20080215895A1 (en) * 1992-12-09 2008-09-04 Discovery Communications, Inc. Electronic book secure communication with home subsystem
US20080213339A1 (en) * 2005-08-02 2008-09-04 Roger Imboden Pharmaceutical Composition Containing Indometacin and/or Acemetacin
US20080251615A1 (en) * 2001-06-29 2008-10-16 Eurand Pharmaceuticals Ltd. Drug activation process and vibrational mill therefor
US20080262078A1 (en) * 2007-04-20 2008-10-23 Namdeo Alok B Pharmaceutical Compositions
US20090054481A1 (en) * 2003-07-11 2009-02-26 Albano Antonio A Saquinavir Mesylate Oral Dosage Form
EP2135611A1 (en) 2001-03-01 2009-12-23 Hollis-Eden Pharmaceuticals Inc. Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US20100081685A1 (en) * 2007-03-29 2010-04-01 Daiichi Sankyo Company, Limited Pharmaceutical composition
US20100092563A1 (en) * 2006-06-30 2010-04-15 Iceutica Pty Ltd. Methods for the Preparation of Biologically Active Compounds in Nanoparticulate Form
US20100297220A1 (en) * 2003-07-18 2010-11-25 Santarus, Inc Pharmaceutical Formulation And Method For Treating Acid-Caused Gastrointestinal Disorders
US7865567B1 (en) 1993-12-02 2011-01-04 Discovery Patent Holdings, Llc Virtual on-demand electronic book
US20110144071A1 (en) * 2008-08-08 2011-06-16 Jesalis Pharma Gmbh Crystalline active ingredient microparticles, method for producing the same and use thereof in drugs
WO2011118960A2 (en) 2010-03-22 2011-09-29 (주)바이오시네틱스 Method for preparing nano-particles
CN102408756A (en) * 2011-08-05 2012-04-11 中国人民解放军第四军医大学 Method for simply preparing DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate) microscopic particles and marking neurons
EP2471536A1 (en) 2004-09-29 2012-07-04 Harbor BioSciences, Inc. Steroid analogs and characterization and treatment methods
WO2013042978A1 (en) 2011-09-21 2013-03-28 (주)바이오시네틱스 Method for preparing nano particles
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US8992982B2 (en) 2009-04-24 2015-03-31 Iceutica Pty Ltd. Formulation of indomethacin
US9173854B2 (en) 2009-04-24 2015-11-03 Iceutica Pty Ltd. Formulation of diclofenac
US9402907B2 (en) 2011-08-10 2016-08-02 Daiichi Sankyo Company, Limited Pharmaceutical composition containing diamine derivative
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US20170105966A1 (en) * 2008-02-28 2017-04-20 Roger Imboden Pharmaceutical composition containing indometacin and/or acemetacin

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE69324504T2 (en) * 1993-01-19 1999-08-26 Warner Lambert Co A stabilized composition comprising orally applicable procedure, the compound ci-981 and
CN1299235A (en) 1998-03-11 2001-06-13 史密丝克莱恩比彻姆公司 Novel composition of eprosartan
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
DE60020732D1 (en) 1999-12-20 2005-07-14 Nicholas J Kerkhof A process for producing nanometer particles by fluidized bed spray drying
US8771740B2 (en) 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
EP1423175B1 (en) 2001-08-08 2013-10-02 Brown University Research Foundation Methods for micronization of hydrophobic drugs
ES2231043B2 (en) * 2004-10-29 2005-10-01 Laboratorios Cinfa, S.A. Pharmaceutical composition ebastina immediate release and its manufacturing process.
JP4754211B2 (en) * 2004-12-28 2011-08-24 ライオン株式会社 Particulate pharmaceutical compositions and a method of manufacturing the same
JP6091041B2 (en) * 2004-12-31 2017-03-08 イシューティカ ピーティーワイ リミテッド Nanoparticle composition and synthetic methods
ES2371414T3 (en) 2005-07-25 2012-01-02 Otsuka Pharmaceutical Co., Ltd. oral preparation to measure the metabolic capacity of the pyrimidine.
CA2644905A1 (en) * 2006-03-06 2007-09-13 Teva Pharmaceutical Industries Ltd. Ezetimibe compositions
JP2007314529A (en) * 2006-04-28 2007-12-06 Lion Corp Granulated particle, tablet and method for producing granulated particle
CA2960377A1 (en) * 2006-06-30 2008-01-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
WO2008126797A1 (en) 2007-04-06 2008-10-23 Activus Pharma Co., Ltd. Method for producing pulverized organic compound particle
JP2009091298A (en) * 2007-10-10 2009-04-30 Asuka Corporation:Kk Skin-revitalizing cosmetic
RU2485947C2 (en) * 2008-02-06 2013-06-27 Вокхардт Рисерч Сентер Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
RU2010136934A (en) * 2008-02-06 2012-03-20 Вокхард Рисерч Сентер (In) The pharmaceutical compositions of entacapone, micronized with sugar alcohols
JP5149673B2 (en) * 2008-04-03 2013-02-20 有限会社不動権現 Konjac flour production method
JP5536654B2 (en) * 2008-09-19 2014-07-02 株式会社アクティバスファーマ Medical composite organic compound powder, a manufacturing method thereof as well as suspensions
EP2168573A1 (en) * 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
WO2010121323A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd Method for the production of commercial nanoparticle and microparticle powders
EP2421530A4 (en) * 2009-04-24 2013-01-16 Iceutica Pty Ltd A novel formulation of metaxalone
KR101679522B1 (en) * 2009-04-24 2016-11-24 아이슈티카 피티와이 리미티드 Method for improving the dissolution profile of a biologically active material
EP2421510A4 (en) * 2009-04-24 2013-01-09 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
US20120148634A1 (en) * 2009-04-24 2012-06-14 Aaron Dodd Novel formulation of naproxen
KR101442069B1 (en) 2009-09-30 2014-09-18 가부시키가이샤 상기 Method for improving the aqueous solubility of poorly-soluble substances
JP5909796B2 (en) 2012-03-02 2016-04-27 株式会社サンギ Water solubility improved method of sparingly soluble substances

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2108032A1 (en) * 1970-09-28 1972-05-12 Controlled Medications Prolonged progressively released oral medicament - comprises a solid excipient and cellulose dicarboxylic acid binder
FR2162245A1 (en) * 1971-12-06 1973-07-20 Sobio Lab Micronized l-dopa - with increased bioavailability
FR2257256A1 (en) * 1974-01-10 1975-08-08 Doubleday Eric
JPS5132718A (en) * 1974-09-13 1976-03-19 Yoshinobu Nakai Nanyoseiyakuhin no yoshutsusokudochosetsuho
GB2159407A (en) * 1982-12-02 1985-12-04 Takada Seiyaku Kabushiki Kaish Solid water-soluble nifedipine preparation
US4753800A (en) * 1985-10-04 1988-06-28 Warner-Lambert Company Medicament adsorbates and their preparation
GB2224207A (en) * 1988-10-28 1990-05-02 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical compositions containing piroxicam

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2257266B1 (en) * 1974-01-10 1977-07-01 Pasteur Institut
JPH0215026A (en) * 1988-07-01 1990-01-18 Takada Seiyaku Kk Novel probucol solid preparation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2108032A1 (en) * 1970-09-28 1972-05-12 Controlled Medications Prolonged progressively released oral medicament - comprises a solid excipient and cellulose dicarboxylic acid binder
FR2162245A1 (en) * 1971-12-06 1973-07-20 Sobio Lab Micronized l-dopa - with increased bioavailability
FR2257256A1 (en) * 1974-01-10 1975-08-08 Doubleday Eric
JPS5132718A (en) * 1974-09-13 1976-03-19 Yoshinobu Nakai Nanyoseiyakuhin no yoshutsusokudochosetsuho
GB2159407A (en) * 1982-12-02 1985-12-04 Takada Seiyaku Kabushiki Kaish Solid water-soluble nifedipine preparation
US4753800A (en) * 1985-10-04 1988-06-28 Warner-Lambert Company Medicament adsorbates and their preparation
GB2224207A (en) * 1988-10-28 1990-05-02 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical compositions containing piroxicam

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Optimization of In Vitro Availability of Diazepam" by S. Leucuta et al., Clujul Medical 1982, vol. LV-No. 1.
"Properties and Dissolution of Drugs Micronized By Crystallization From Supercritical Gases", by H. Loth et al., International Journal of Pharmaceutics, vol. 32, 1986, pp. 265-267.
H. Sekikawa et al., Chem. Pharm. Bull., vol 26, pp. 3033 3039 (1978). *
H. Sekikawa et al., Chem. Pharm. Bull., vol 26, pp. 3033-3039 (1978).
N. Kaneniwa et al., Chem. Pharm. Bull., vol. 23, pp. 2973 2986 (1975). *
N. Kaneniwa et al., Chem. Pharm. Bull., vol. 23, pp. 2973-2986 (1975).
Nature, vol. 193, pp. 588 589 (1962). *
Nature, vol. 193, pp. 588-589 (1962).
Optimization of In Vitro Availability of Diazepam by S. Leucuta et al., Clujul Medical 1982, vol. LV No. 1. *
Properties and Dissolution of Drugs Micronized By Crystallization From Supercritical Gases , by H. Loth et al., International Journal of Pharmaceutics, vol. 32, 1986, pp. 265 267. *
Remingtons Pharmaceutical Sciences, 1988 Edition Mack Publishing Co. *
Yakugaku Zasshi, vol. 101, No. 8, pp. 723 732 (1981). *
Yakugaku Zasshi, vol. 101, No. 8, pp. 723-732 (1981).

Cited By (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460829A (en) * 1991-12-03 1995-10-24 Rhone-Poulenc Rorer S.A. Pharmaceutical compositions based on ebastine or analogues thereof
US5302400A (en) * 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US20080215895A1 (en) * 1992-12-09 2008-09-04 Discovery Communications, Inc. Electronic book secure communication with home subsystem
US20110185191A2 (en) * 1992-12-09 2011-07-28 Adrea Llc Electronic book electronic links
US20080160095A1 (en) * 1993-02-22 2008-07-03 Abraxis Bioscience, Llc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070122468A1 (en) * 1993-02-22 2007-05-31 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070191473A1 (en) * 1993-02-22 2007-08-16 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070122465A1 (en) * 1993-02-22 2007-05-31 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070117862A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070128290A1 (en) * 1993-02-22 2007-06-07 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6846801B1 (en) 1993-06-24 2005-01-25 Astrazeneca Ab Systemic administration of a therapeutic preparation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5952008A (en) * 1993-06-24 1999-09-14 Ab Astra Processes for preparing compositions for inhalation
US20040171550A1 (en) * 1993-06-24 2004-09-02 Astrazeneca Ab, A Swedish Corporation Compositions for inhalation
US6306440B1 (en) 1993-06-24 2001-10-23 Astrazeneca Ab Therapeutic preparation for inhalation
US20030216541A1 (en) * 1993-06-24 2003-11-20 Astrazeneca Ab, A Swedish Corporation Systemic administration of a therapeutic preparation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US5658878A (en) * 1993-06-24 1997-08-19 Ab Astra Therapeutic preparation for inhalation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US20030211972A1 (en) * 1993-06-24 2003-11-13 Astrazeneca Ab, A Sweden Corporation Systemic administration of a therapeutic preparation
US7865567B1 (en) 1993-12-02 2011-01-04 Discovery Patent Holdings, Llc Virtual on-demand electronic book
US6165976A (en) * 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6610653B1 (en) 1994-06-23 2003-08-26 Astrazeneca Ab Therapeutic preparation for inhalation
US5730997A (en) * 1994-08-01 1998-03-24 Kv Pharmaceutical Company Tastemasked liquid pharmaceutical delivery system
USRE37516E1 (en) 1994-10-06 2002-01-15 Cephalon, Inc. Acetamide derivative having defined particle size
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US6932962B1 (en) 1994-12-22 2005-08-23 Astrazeneca Ab Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides
US6004574A (en) * 1994-12-22 1999-12-21 Astra Aktiebolag Powder formulations containing melezitose as a diluent
US6436902B1 (en) 1994-12-22 2002-08-20 Astrazeneca Ab Therapeutic preparations for inhalation
US20030064928A1 (en) * 1994-12-22 2003-04-03 Astra Aktiebolag, A Sweden Corporation Therapeutic preparations for inhalation
US5503723A (en) * 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US6894064B2 (en) 1996-03-26 2005-05-17 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
US20040180932A1 (en) * 1996-03-26 2004-09-16 Arbuthnot Gordon Nelson Benzothiophenes, formulations containing same, and methods
US20050239840A1 (en) * 1996-03-26 2005-10-27 Arbuthnot Gordon N Benzothiophenes, formulations containing same, and methods
US8030330B2 (en) 1996-03-26 2011-10-04 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US6797719B2 (en) 1996-03-26 2004-09-28 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
US20100255106A1 (en) * 1996-03-26 2010-10-07 Gordon Nelson Arbuthnot Benzothiophenes, formulations containing same, and methods
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US6197347B1 (en) 1998-06-29 2001-03-06 Andrx Pharmaceuticals, Inc. Oral dosage for the controlled release of analgesic
US6238703B1 (en) 1998-06-29 2001-05-29 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form of ketoprofen
US6432448B1 (en) * 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US7144585B1 (en) 1999-03-25 2006-12-05 Otsuka Pharmaceutical Co., Ltd. Cilostazol preparation
US20060058272A1 (en) * 1999-08-31 2006-03-16 Juergen Hilman Pharmaceutical composition for use as a contraceptive
US20030129238A1 (en) * 1999-10-29 2003-07-10 Michael Augello Edible MCC/PGA coating composition
WO2002013823A1 (en) * 2000-08-14 2002-02-21 Teva Pharmaceutical Industries Ltd. Micronized torsemide
US20050095272A1 (en) * 2000-11-28 2005-05-05 Fmc Corporation Edible PGA coating composition
US6699315B2 (en) 2000-11-28 2004-03-02 Fmc Corporation Edible PGA coating composition
US6544552B2 (en) 2001-01-11 2003-04-08 Particle And Coating Technologies, Inc. Method of producing porous tablets with improved dissolution properties
EP2135611A1 (en) 2001-03-01 2009-12-23 Hollis-Eden Pharmaceuticals Inc. Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy
US7793871B2 (en) * 2001-06-29 2010-09-14 Eurand Pharmaceuticals Ltd. Drug activation process and vibrational mill therefor
US20080251615A1 (en) * 2001-06-29 2008-10-16 Eurand Pharmaceuticals Ltd. Drug activation process and vibrational mill therefor
WO2007064311A1 (en) * 2001-07-10 2007-06-07 Teva Pharmaceutical Industries Ltd. Micronized mirtazapine
US20060002974A1 (en) * 2002-06-21 2006-01-05 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7011842B1 (en) 2002-06-21 2006-03-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7070798B1 (en) 2002-06-21 2006-07-04 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US9084671B2 (en) 2002-06-21 2015-07-21 Advanced Cardiovascular Systems, Inc. Methods of forming a micronized peptide coated stent
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US7803406B2 (en) 2002-06-21 2010-09-28 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7033602B1 (en) 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7875286B2 (en) 2002-06-21 2011-01-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US20060062821A1 (en) * 2002-06-21 2006-03-23 Simhambhatla Murthy V Polycationic peptide coatings and methods of making the same
US6994867B1 (en) 2002-06-21 2006-02-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing L-arginine
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7901703B2 (en) 2002-06-21 2011-03-08 Advanced Cardiovascular Systems, Inc. Polycationic peptides for cardiovascular therapy
US8067023B2 (en) 2002-06-21 2011-11-29 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating plasma polymerized film layers and charged amino acids
US7803394B2 (en) 2002-06-21 2010-09-28 Advanced Cardiovascular Systems, Inc. Polycationic peptide hydrogel coatings for cardiovascular therapy
US7794743B2 (en) 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US8580308B2 (en) 2002-07-12 2013-11-12 Cephalon, Inc. Modafinil pharmaceutical compositions
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US20070065517A1 (en) * 2002-07-12 2007-03-22 Cephalon, Inc. Modafinil Pharmaceutical Compositions
US7094256B1 (en) 2002-12-16 2006-08-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical device containing polycationic peptides
US20050079138A1 (en) * 2002-12-19 2005-04-14 Chickering Donald E. Methods for making pharmaceutical formulations comprising microparticles with improved dispersibility, suspendability or wettability
US20060093677A1 (en) * 2002-12-19 2006-05-04 Chickering Donald E Iii Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20060093678A1 (en) * 2002-12-19 2006-05-04 Chickering Donald E Iii Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20040146537A1 (en) * 2003-01-28 2004-07-29 Ramachandran Radhakrishnan Oily wax matrix suspension formulation comprising pharmacologically active agents
US20060160903A1 (en) * 2003-02-24 2006-07-20 Sidney Liang Process for preparing benzhydrylthioacetamide
US7244865B2 (en) 2003-02-24 2007-07-17 Mallinckrodt Inc. Process for preparing benzhydrylthioacetamide
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
US20100112045A1 (en) * 2003-04-29 2010-05-06 Cephalon, Inc. Surface-treated modafinil particles
US20090054481A1 (en) * 2003-07-11 2009-02-26 Albano Antonio A Saquinavir Mesylate Oral Dosage Form
US20100297220A1 (en) * 2003-07-18 2010-11-25 Santarus, Inc Pharmaceutical Formulation And Method For Treating Acid-Caused Gastrointestinal Disorders
US20140370104A1 (en) * 2003-07-18 2014-12-18 Santarus, Inc. Pharmaceutical formulation and method for treating acid caused gastrointestinal disorders
US20060255323A1 (en) * 2003-11-28 2006-11-16 Mitsubishi Chemichal Corporation Process for producing fine particles of organic compound
US20050152983A1 (en) * 2004-01-08 2005-07-14 Wyeth Directly compressible pharmaceutical composition for the oral administration of CCI-779
EP2471536A1 (en) 2004-09-29 2012-07-04 Harbor BioSciences, Inc. Steroid analogs and characterization and treatment methods
US20080213339A1 (en) * 2005-08-02 2008-09-04 Roger Imboden Pharmaceutical Composition Containing Indometacin and/or Acemetacin
KR101409302B1 (en) * 2005-08-02 2014-06-20 드로싸팜 아게 Pharmaceutical composition containing indometacin and/or acemetacin
US20070092576A1 (en) * 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
US20070148211A1 (en) * 2005-12-15 2007-06-28 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US20070178166A1 (en) * 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US8808751B2 (en) 2006-06-30 2014-08-19 Iceutica Pty Ltd. Methods for the preparation of biologically active compounds in nanoparticulate form
US20100092563A1 (en) * 2006-06-30 2010-04-15 Iceutica Pty Ltd. Methods for the Preparation of Biologically Active Compounds in Nanoparticulate Form
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
US9707296B2 (en) 2007-03-29 2017-07-18 Daiichi Sankyo Company, Limited Pharmaceutical composition
US9149532B2 (en) 2007-03-29 2015-10-06 Daiichi Sanykyo Company, Limited Pharmaceutical composition
US20100081685A1 (en) * 2007-03-29 2010-04-01 Daiichi Sankyo Company, Limited Pharmaceutical composition
US20080262078A1 (en) * 2007-04-20 2008-10-23 Namdeo Alok B Pharmaceutical Compositions
US20170105966A1 (en) * 2008-02-28 2017-04-20 Roger Imboden Pharmaceutical composition containing indometacin and/or acemetacin
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US9173843B2 (en) 2008-08-08 2015-11-03 Jesalis Pharma Gmbh Crystalline active ingredient microparticles, method for producing the same and use thereof in drugs
US20110144071A1 (en) * 2008-08-08 2011-06-16 Jesalis Pharma Gmbh Crystalline active ingredient microparticles, method for producing the same and use thereof in drugs
US9180096B2 (en) 2009-04-24 2015-11-10 Iceutica Pty Ltd. Formulation of diclofenac
US8992982B2 (en) 2009-04-24 2015-03-31 Iceutica Pty Ltd. Formulation of indomethacin
US9089471B2 (en) 2009-04-24 2015-07-28 Iceutica Pty Ltd. Formulation of indomethacin
US9186328B2 (en) 2009-04-24 2015-11-17 Iceutica Pty Ltd. Formulation of diclofenac
US9522135B2 (en) 2009-04-24 2016-12-20 Iceutica Pty Ltd. Formulation of indomethacin
US9849111B2 (en) 2009-04-24 2017-12-26 Iceutica Pty Ltd. Formulation of indomethacin
US9173854B2 (en) 2009-04-24 2015-11-03 Iceutica Pty Ltd. Formulation of diclofenac
US9180095B2 (en) 2009-04-24 2015-11-10 Iceutica Pty Ltd. Formulation of diclofenac
US9095496B2 (en) 2009-04-24 2015-08-04 Iceutica Pty Ltd. Formulation of indomethacin
US8828445B2 (en) 2010-03-22 2014-09-09 Bio-Synectics Inc. Method for preparing nano-particles utilizing a saccharide anti-coagulant
WO2011118960A2 (en) 2010-03-22 2011-09-29 (주)바이오시네틱스 Method for preparing nano-particles
CN102408756B (en) 2011-08-05 2013-06-19 中国人民解放军第四军医大学 Method for simply preparing DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate) microscopic particles and marking neurons
CN102408756A (en) * 2011-08-05 2012-04-11 中国人民解放军第四军医大学 Method for simply preparing DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate) microscopic particles and marking neurons
US9402907B2 (en) 2011-08-10 2016-08-02 Daiichi Sankyo Company, Limited Pharmaceutical composition containing diamine derivative
US9439871B2 (en) 2011-09-21 2016-09-13 Bio-Synectics, Inc. Method for preparing nano particles
WO2013042978A1 (en) 2011-09-21 2013-03-28 (주)바이오시네틱스 Method for preparing nano particles
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US9649318B2 (en) 2014-06-09 2017-05-16 Iceutica Pty Ltd. Formulation of meloxicam
US9808468B2 (en) 2014-06-09 2017-11-07 Iceutica Pty Ltd. Formulation of meloxicam

Also Published As

Publication number Publication date Type
EP0411629B1 (en) 1993-11-03 grant
JP2642486B2 (en) 1997-08-20 grant
DK0411629T3 (en) 1993-12-13 grant
DE69004372T2 (en) 1994-04-21 grant
CA2022465A1 (en) 1991-02-05 application
KR0126465B1 (en) 1997-12-24 grant
JPH0366613A (en) 1991-03-22 application
EP0411629A2 (en) 1991-02-06 application
EP0411629A3 (en) 1991-05-08 application
DE69004372D1 (en) 1993-12-09 grant
CA2022465C (en) 1998-04-21 grant
ES2062221T3 (en) 1994-12-16 grant

Similar Documents

Publication Publication Date Title
US4404183A (en) Sustained release pharmaceutical composition of solid medical material
US6180138B1 (en) Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US5573783A (en) Redispersible nanoparticulate film matrices with protective overcoats
US6682761B2 (en) Water-insoluble drug particle process
US6973741B2 (en) Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
US4880623A (en) Process for the preparation of solid nifedipine formulations of high bioavailability and with sustained effect, and formulations thus obtained
US7078057B2 (en) Process for producing nanometer particles by fluid bed spray-drying
US6383517B1 (en) Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US5622938A (en) Sugar base surfactant for nanocrystals
US20030087308A1 (en) Method for high through put screening using a small scale mill or microfluidics
US20060210640A1 (en) Process for producing nanoparticles by spray drying
EP0901786B1 (en) Solid pharmaceutical dispersions with enhanced bioavailability
US20030049323A1 (en) Process to precipitate drug particles
US20020081266A1 (en) Spray dried powders for pulmonary or nasal administration
US6756062B2 (en) Preparation of drug particles using evaporation precipitation into aqueous solutions
US20050058705A1 (en) Immediate release pharmaceutical granule compositions and a continuous process for making them
US6221400B1 (en) Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors
US6068858A (en) Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US5972381A (en) Solid solution of an antifungal agent with enhanced bioavailability
US20030180367A1 (en) Microparticles of water-insoluble substances
US4639370A (en) Pharmaceutical composition
Barzegar-Jalali et al. Cogrinding as an approach to enhance dissolution rate of a poorly water-soluble drug (gliclazide)
US4562069A (en) Two-phase formulation
JP2001131071A (en) Amorphous substance and medical composition containing amorphous substance
WO1999025343A1 (en) Granules comprising clavulanate and one or more excipients

Legal Events

Date Code Title Description
AS Assignment

Owner name: TANABE SEIYAKU CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:SAMEJIMA, MASAYOSHI;NODA, KAZUO;KOBAYASHI, MASAO;AND OTHERS;REEL/FRAME:005400/0009;SIGNING DATES FROM 19900709 TO 19900712

PTEF Application for a patent term extension

Free format text: PRODUCT NAME: KADIAN (MORPHINE SULFATE; REQUESTED FOR 81 DAYS

Filing date: 19960904

Expiry date: 20100413

FPAY Fee payment

Year of fee payment: 4

PTER Rejection of a patent term extension

Free format text: PRODUCT NAME: KADIAN (MORPHINE SULFATE

Filing date: 19960904

Expiry date: 20100413

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Expired due to failure to pay maintenance fee

Effective date: 20010413